Stockscreener 앱 받기
0.00
100.00%
-29.08
시간 외 거래:
29.30
29.30
+
전일 마감가:
$29.08
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$145.36M
수익:
$34.77M
순이익/손실:
$-74.04M
주가수익비율:
0.00
EPS:
-8.0157
순현금흐름:
$-79.76M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$30.39
Mersana Therapeutics Inc Stock (MRSN) Company Profile
명칭
Mersana Therapeutics Inc
전화
617-498-0020
주소
840 MEMORIAL DRIVE, CAMBRIDGE
Compare MRSN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.00 | 145.36M | 34.77M | -74.04M | -79.76M | -8.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-06 | 개시 | William Blair | Outperform |
| 2024-11-15 | 재개 | Citigroup | Buy |
| 2024-03-19 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-07-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-07-27 | 다운그레이드 | Truist | Buy → Hold |
| 2023-07-27 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-06-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-06-15 | 개시 | Guggenheim | Buy |
| 2023-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-20 | 개시 | Citigroup | Buy |
| 2022-11-21 | 개시 | Truist | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-08-30 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | Credit Suisse | Neutral |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-04-29 | 개시 | BTIG Research | Buy |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-11-14 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
Mersana Therapeutics Inc 주식(MRSN)의 최신 뉴스
Does Mersana Therapeutics Inc have pricing power2026 Support & Resistance & Technical Pattern Based Signals - baoquankhu1.vn
Day One Biopharmaceuticals Acquires Mersana Therapeutics: Key Financial Details, Purchase Price, and Pro Forma Impact - Minichart
Setup Watch: How is Mersana Therapeutics Inc. managing supply chain issues2026 Opening Moves & Daily Profit Focused Stock Screening - baoquankhu1.vn
Can Mersana Therapeutics Inc. (0M4) stock double in coming years2026 Big Picture & Detailed Earnings Play Strategies - Naître et grandir
Is Mersana Therapeutics Inc. stock a smart buy before Fed meetingGap Up & Low Risk Investment Opportunities - Naître et grandir
Aug Patterns: Is Mersana Therapeutics Inc a top pick in the sectorJuly 2025 Decliners & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Guidance Update: Does Mersana Therapeutics Inc have pricing powerWeekly Trend Summary & AI Enhanced Trading Signals - baoquankhu1.vn
MRSN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Day One Weighs OJEMDA Momentum Against Expanded Oncology Pipeline Risks - Sahm
Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead (NASDAQ:DAWN) - Seeking Alpha
Day One Highlights Transformational 2025 and OJEMDA Growth - TipRanks
Cancer drug OJEMDA powers Day One’s $155M year, bigger 2026 sales target set - Stock Titan
Day One Biopharmaceuticals earnings up next after Mersana deal - Investing.com Australia
Day One Biopharmaceuticals earnings up next after Mersana deal By Investing.com - Investing.com Canada
Market Outlook: Is Mersana Therapeutics Inc benefiting from interest rate changesJuly 2025 Drop Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
How Mersana Therapeutics Inc. stock performs in weak economyJuly 2025 Setups & Daily Profit Focused Screening - mfd.ru
Resistance Check: How is Mersana Therapeutics Inc managing supply chain issuesTrade Analysis Report & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Growth Report: Can Mersana Therapeutics Inc. stock sustain revenue growth2025 Fundamental Recap & AI Forecasted Entry and Exit Points - mfd.ru
Published on: 2026-02-14 07:10:10 - mfd.ru
Is Mersana Therapeutics Inc. forming a bullish divergenceMarket Trend Review & Fast Gaining Stock Strategy Reports - mfd.ru
Can Mersana Therapeutics Inc. withstand a market correctionEarnings Growth Summary & Weekly High Conviction Trade Ideas - mfd.ru
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026 - GlobeNewswire
Day One Biopharma to review Q4 and 2025 results in Feb. 24 webcast - Stock Titan
Is Mersana Therapeutics Inc a top pick in the sectorJuly 2025 Highlights & Verified Momentum Watchlists - baoquankhu1.vn
Aug Sentiment: What are Mersana Therapeutics Incs recent SEC filings showing2025 Market WrapUp & Precise Swing Trade Alerts - baoquankhu1.vn
Gap Down: Is Rockwell Automation Inc stock good for income investorsJuly 2025 Institutional & Breakout Confirmation Trade Signals - baoquankhu1.vn
Weekly Trades: What is the next catalyst for The Marygold Companies Inc2025 Earnings Surprises & Daily Stock Momentum Reports - baoquankhu1.vn
Income Plays: How analysts rate Mersana Therapeutics Inc stock today2025 Geopolitical Influence & Fast Momentum Entry Tips - Bộ Nội Vụ
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Sees Large Drop in Short Interest - MarketBeat
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance - The Manila Times
Day One Biopharmaceuticals Reports 172% Year-over-Year Growth in 2025 Net Product Revenue, Projects 2026 Revenue Between $225 Million and $250 Million - Quiver Quantitative
Cancer drug OJEMDA sales jump 172% in 2025 as Day One sets 2026 target - Stock Titan
Is Mersana Therapeutics Inc. stock positioned for long term growthJuly 2025 Action & AI Forecast for Swing Trade Picks - Улправда
Day One Biopharmaceuticals Stock Pre-Market (+5.4%) : Market Digests Mersana Acquisition - Trefis
Mersana Therapeutics (NASDAQ:MRSN) Upgraded at Wall Street Zen - MarketBeat
Is Mersana Therapeutics Inc. stock a buy on dipsWeekly Profit Report & Risk Controlled Swing Alerts - Улправда
Will Mersana Therapeutics Inc. stock maintain growth storyWeekly Trade Report & Fast Gain Stock Tips - Улправда
Published on: 2026-01-09 13:08:50 - Улправда
Is Mersana Therapeutics Inc. stock a buy before product launches2025 Technical Overview & AI Powered Trade Plan Recommendations - Улправда
Free cash flow of Mersana Therapeutics, Inc. – LSX:A41BV2 - TradingView — Track All Markets
How The Day One Deal Is Reshaping The Story For Mersana Therapeutics (MRSN) - Yahoo Finance
Day One concludes Mersana Therapeutics acquisition - Yahoo Finance
Mersana Therapeutics, Inc.Common Stock (NQ: MRSN - FinancialContent
Mersana Therapeutics Completes Merger and Delists from Nasdaq - The Globe and Mail
Day One Biopharmaceuticals completes acquisition of Mersana Therapeutics By Investing.com - Investing.com Nigeria
Day One Biopharmaceuticals completes acquisition of Mersana Therapeutics - Investing.com
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics - TipRanks
Mersana Therapeutics Announces Board and Management Changes Following Merger - TradingView — Track All Markets
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics to Enhance Oncology Pipeline - Quiver Quantitative
Day One Completes Acquisition of Mersana Therapeutics - The Manila Times
Day One buys Mersana to advance drug for rare salivary cancer - Stock Titan
Mersana Therapeutics Inc (MRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
1.21%
자본화:
|
볼륨(24시간):